Abstract 198P
Background
Immunotherapy for cancer is closely related to the tumor immunosuppressive microenvironment (TIME). Resiquimod (a mixed TLR7/8 agonist also known as R848) has been shown to mediate promising immunostimulatory activity in a variety of preclinical models. Poly(D, L-lactic-co-glycolic acid) (PLGA) is one of the most commonly used biodegradable polymer.
Methods
The nanoparticles loaded with R848 (CD@R848@NP) were prepared by improved emulsion-solvent evaporation method, and the drug loading rate and entrapment efficiency were calculated. Its physical and chemical properties and drug release stability were measured, and its polarization effect on macrophages was evaluated in vitro. After labeling with IR780 fluorescent dye, the localization of the nanoparticles in vivo and in vitro was analyzed. CD@R848@NP was used to treat MC38 colon cancer mice by tail vein injection combined with intraperitoneal injection of TNFR2 antibody.
Results
(1) The prepared CD@R848@NP nanoparticles have strong stability, no obvious cytotoxicity, sustained release effect and increased release under acidic conditions. The load content (LC) and entrapment efficiency (EE) of R848 were (3.11 ±0.61)% and (65.36 ±3)%. (2) In vitro experiments showed that HP-β-CD modified nanoparticles could be better absorbed by macrophages, and in vivo localization experiments confirmed that they could be better located in tumor tissues. (3) CD@R848@NP combined with Anti-TNFR2 could eliminate MC38 tumor in mice, and there was no significant change in body weight. Hue results showed that the nanoparticles had no obvious toxicity to all organs. After 24 hours of administration, the secretion of IL-12 factor in blood of mice was significantly higher than that of other groups. The results of tumor histochemistry showed that the secretion of TNF α and IL-6 factors in CD@R848@NP was significantly higher than that in other groups.
Conclusions
PLGA nanoparticles encapsulated with R848 can effectively deliver drugs to tumor tissue and induce tumor-associated macrophages to polarize into M1 macrophages. On the other hand, TNFR2 antibodies can inhibit the activation of Treg cells, reduce immunosuppression in tumor microenvironment and eliminate tumor.
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China (82060308), Guizhou Immunotherapy Research Talent Base (RCJD2018-11).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
189P - The impact of immune microenvironment subopopulations on soft tissue sarcomas
Presenter: Shokhrukhbek Khujaev
Session: Poster Display
190P - Immune-related roles of B7H3 in glioblastoma
Presenter: Arnaud Simonet
Session: Poster Display
191P - Senolytic treatment remodels glioblastoma microenvironment
Presenter: Alexa Saliou
Session: Poster Display
192P - Analysis of Tumor-Associated Macrophages and Tumor-infiltrating Lymphocytes within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases
Presenter: Markus Kleinberger
Session: Poster Display
193P - Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibit anti-cancer immunity via CCL2
Presenter: Ronja Wieboldt
Session: Poster Display
194P - Achieving Reproducible Maturation Staging of Tertiary Lymphoid Structures: from Imaging Mass Cytometry Data to Pathology Applications
Presenter: Marion Le Rochais
Session: Poster Display
195P - IMMUcan - Toward a better understanding of the tumor microenvironment to inform precision oncology approaches.
Presenter: Marie Morfouace
Session: Poster Display
196P - Local glycan engineering induces systemic antitumor immune reactions via antigen cross-presentation
Presenter: Natalia Rodrigues Mantuano
Session: Poster Display
197P - Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score
Presenter: Daniel Tiezzi
Session: Poster Display
199P - Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium
Presenter: Nils Eling
Session: Poster Display